- Research highlight
- Open Access
The rationale for preventing cancer cachexia: targeting excessive fatty acid oxidation
Chinese Journal of Cancervolume 35, Article number: 67 (2016)
Cachexia commonly occurs at the terminal stage of cancer and has largely unclear molecular mechanisms. A recent study published in Nature Medicine, entitled “Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia,” reveals that cachectic cancer cells can secrete multiple cytokines that induce excessive fatty acid oxidation, which is responsible for muscle loss in cancer cachexia. Inhibition of fatty acid oxidation using etomoxir can increase muscle mass and body weight in cancer cachexia animal models. The usage of stable cachexia animal models is also discussed in this research highlight.
In the terminal stages of many chronic diseases, including cancer, loss of body mass may occur, which cannot be prevented or corrected by nutritional supplementation. This condition is termed cachexia, defined as >5% weight loss within 6 months. In addition to the loss of adipose tissue and overall metabolic imbalance, a typical characteristic of cachexia is muscle atrophy, resulting in fatigue and fetal weakness. Cancer cachexia is commonly observed in up to 80% of patients with advanced-stage disease and is one of the primary causes of cancer-related morbidity and mortality [1–3]. In fact, in cancer patients receiving radical therapy, cachexia can also occur. In patients with nasopharyngeal carcinoma from endemic areas, whose tumors are naturally sensitive to radiotherapy [4, 5], cachexia can be induced by radical radiotherapy in patients with post-irradiation nasopharyngeal necrosis . Even worse, cachexia can usually induce resistance against conventional anti-cancer therapies, and no drug has been approved to treat or prevent cachexia in current medical practice .
It is believed that early diagnosis of and intervention in cancer cachexia can control its fetal progression, improve a patient’s quality of life, and prolong survival . However, the underlying molecular mechanisms of cancer cachexia are largely unclear, preventing the development of effective intervention approaches. In a study recently published in Nature Medicine, entitled “Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia,” Fukawa et al.  report their interesting findings that cachectic cancer cells secrete multiple inflammatory factors, including interleukin-6 and tumor necrosis factor-alpha, which have been suspected to play roles in cancer cachexia for decades [10, 11]. This secretion results in fatty acid oxidation and activation of a p38 stress-response signature in the skeletal muscles before presentation of cachectic muscle atrophy.
In this study, the authors also demonstrate that blockade of fatty acid oxidation using etomoxir can rescue human myotubes in vitro and can increase muscle mass and body weight in cancer cachexia animal models . Therefore, targeting fatty acid-induced oxidative stress has a great potential for preventing cancer-induced cachexia.
The application of stable cachexia animal models is one of the strengths of this study. As shown in Fig. 1, the human clear cell renal cell carcinoma cell line RXF393 can stably induce cachexia in nude mice after several weeks of subcutaneous inoculation or orthotopic inoculation of the cancer cells into the subrenal capsule area.
Much more information can be found in the authors’ dataset from high-throughput expression profiling of human myotubes after exposure to cachectic or non-cachectic conditioned media . The involvement of multiple cytokines reported in this comprehensive study also indicates that certain other causal factors may play a role in cancer cachexia, and especially those factors responsible for adipose tissue rearrangement.
Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14(1):58–74.
Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90–9.
Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66.
Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014;33(8):381–7.
Xu BQ, Tu ZW, Tao YL, Liu ZG, Li XH, Yi W, et al. Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center. Chin J Cancer. 2016;35(1):37.
Hua YJ, Chen MY, Qian CN, Hong MH, Zhao C, Guo L, et al. Postradiation nasopharyngeal necrosis in the patients with nasopharyngeal carcinoma. Head Neck. 2009;31(6):807–12.
Johnston AJ, Hoogenraad NJ. Fn14: a new player in cancer-induced cachexia. Curr Opin Clin Nutr Metab Care. 2016;19(4):316–8.
Dell DD. Cachexia in patients with advanced cancer. Clin J Oncol Nurs. 2002;6(4):235–8.
Fukawa T, Yan-Jiang BC, Min-Wen JC, Jun-Hao ET, Huang D, Qian CN, et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med. 2016;22(6):666–71.
Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52(15):4113–6.
Lonnroth C, Moldawer LL, Gelin J, Kindblom L, Sherry B, Lundholm K. Tumor necrosis factor-alpha and interleukin-1 alpha production in cachectic, tumor-bearing mice. Int J Cancer. 1990;46(5):889–96.
The author declare that he has no competing interests.